Markets:

Overview

News

Currencies

International

Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

133.00 -3.84 (-2.81%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Protagonist Therapeutics, Inc. - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Investigation Reminder: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

April 29, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Regulatory Compliance

Investigation Alert: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

April 29, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Topics Regulatory Compliance

Mid-Afternoon Market Update: Crude Oil Rises Over 3%; Protagonist Therapeutics Shares Plummet ↗

April 26, 2022

U.S. stocks remained lower toward the end of trading, with the Dow Jones tumbling more than 500 points on Tuesday.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

April 26, 2022

During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

April 26, 2022

Via Benzinga

Why Protagonist Therapeutics Shares Are Crashing Today ↗

April 26, 2022

Via Benzinga

Protagonist Therapeutics Earns $25M Milestone Payment From Janssen Biotech ↗

March 16, 2022

Via Benzinga

71 Biggest Movers From Yesterday ↗

April 27, 2022

Gainers Evoke Pharma, Inc. (NASDAQ: EVOK) shares jumped 118.5% to close at $0.86 on Tuesday. The FDA granted new drug product exclusivity to Evoke Pharma's Gimoti (...

Via Benzinga

Stocks Flounder As Wall Street Rotates Out Of Tech ↗

April 26, 2022

Big Tech stocks are struggling ahead of several key earnings reports.

Via Talk Markets

Mid-Day Market Update: Nasdaq Down 400 Points; Arch Resources Shares Jump ↗

April 26, 2022

U.S. stocks extended losses midway through trading, with the Nasdaq Composite dropping 400 points on Tuesday.

Via Benzinga

34 Stocks Moving In Tuesday's Mid-Day Session ↗

April 26, 2022

Gainers Avadel Pharmaceuticals plc. (NASDAQ: AVDL) shares gained 36.3% to $5.74. Shares closed down 36% on Monday, seemingly on no news. Avadel issued a press release Tuesday...

Via Benzinga

The Daily Biotech Pulse - Tuesday, April,26 ↗

April 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Talk Markets

Futures Slide Ahead Of Tech Earnings Deluge ↗

April 26, 2022

Markets in general are preoccupied by the prospect of tighter monetary policy conditions from global central banks to stem rising prices.

Via Talk Markets

Mid-Morning Market Update: Markets Open Lower; Dow Dips 300 Points ↗

April 26, 2022

U.S. stocks traded lower this morning, with the Dow Jones dropping around 300 points on Tuesday.

Via Benzinga

The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy ↗

April 26, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

April 26, 2022

Via Benzinga

18 Stocks Moving in Tuesday's Pre-Market Session ↗

April 26, 2022

Gainers Q&K International Group Limited (NASDAQ: QK) shares rose 59.2% to $1.56 in pre-market trading after dropping around 5% on Monday. Agile Therapeutics, Inc. (NASDAQ:...

Via Benzinga

Protagonist Therapeutics Topline Data from Phase 2 IDEAL Study of PN-943 (450 mg BID) Miss Primary Endpoint ↗

April 25, 2022

Protagonist Therapeutics (NASDAQ: PTGX) announced top-line results from the Phase 2 IDEAL clinical study evaluating PN-943 in patients with moderate-to-severe ulcerative colitis (UC).

Via Benzinga

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

April 21, 2022

From The Schall Law Firm

Via Business Wire

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. With Losses of $100,000 to Contact the Firm

April 20, 2022

From The Schall Law Firm

Via Business Wire

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

April 20, 2022

Gainers

Via Benzinga

EQUITY ALERT: Rosen Law Firm Encourages Protagonist Therapeutics, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – PTGX

April 20, 2022

From The Rosen Law Firm, P.A.

Via Business Wire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

April 14, 2022

Gainers

Via Benzinga

Protagonist Therapeutics Dives As Its Drama Continues With A New FDA Concern ↗

April 14, 2022

The FDA could revoke a key designation for one of Protagonist's leading drugs.

Via Investor's Business Daily

51 Biggest Movers From Thursday ↗

April 18, 2022

Gainers MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 69.4% to close at $2.44 on Thursday. Ally Bridge Group recently reported a purchase of 21.176 million shares of...

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More ↗

April 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

April 14, 2022

The biggest pre-market stock movers for Thursday are ready and waiting so let's see what's moving the market this morning!

Via InvestorPlace

FDA Intends To Revoke Protagonist Therapeutics' Rusfertide Breakthrough Tag In Rare Form Of Blood Cancer ↗

April 14, 2022

Protagonist Therapeutics Inc (NASDAQ: PTGX)

Via Benzinga

Protagonist Therapeutics's Return On Capital Employed Overview ↗

March 03, 2022

Benzinga Pro data, Protagonist Therapeutics (NASDAQ:PTGX) reported Q4 sales of $8.62 million. Earnings fell to a loss of $36.91 million, resulting in a 9.18% decrease from last...

Via Benzinga

3 Desirable Drug Stocks With Very Promising Pipelines ↗

February 16, 2022

Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider.

Via InvestorPlace

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.